Arcturus Therapeutics (ARCT) Misses Q2 EPS by $3.55
Tweet
Share
E-mailGet Alerts ARCT Hot Sheet
Join SI Premium – FREE
Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($0.34), $3.55 worse than the analyst estimate of $3.21. Revenue for the quarter came in at $0 versus the consensus estimate of $191.77 million.
For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blue Owl leads $2.4 billion debt deal for Iren data center
- Jiayin Group (JFIN) Reports Q2 Loss of RMB3.56
- Hafnia Limited (HAFN) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
